First Clinical Trial on Activated Regulatory T Cells: Promising Breakthrough in Preventing the Dreaded Transplant Complication A team from University Medical Center Mainz and [...]
Publication Milestone: Actileucel First-in-Human Results Published in Transplantation and Cellular Therapy We're excited to share that our manuscript on Actileucel has been published in Transplantation [...]
Biotechfirma aus Mainz entwickelt Zelltherapie bei Blutkrebs Das kleine Biotech-Unternehmen ActiTrexx aus Mainz steht vor dem Durchbruch. Eine weltweit einzigartige Zelltherapie zur Behandlung bei [...]
ActiTrexx completes treatment of last patient with novel regulatory T cell therapy against Graft-versus-Host Disease Phase Ib/II study with Actileucel, a novel cellular product [...]
Interview with Aurelius Lie from SpacewalkTalks 2025 | Video On April 3rd, 2025, ActiTrexx had the great opportunity to speak with Aurelius Lie from [...]
Falling Walls 2024. Science Breakthroughs of the Year 2024 | Pitches ActiTrexx has been awarded the main prize in the Science Start-Ups category. The [...]
Mainz, Germany, 19 March 2024 – ActiTrexx GmbH, a clinical-stage company focusing on the activation of regulatory T cells, has treated the first patient with [...]
ActiTrexx erhält den mit 15.000 Euro dotierten ersten Preis für die Entwicklung der „ATreg“ Zelltherapie. Read more: https://isb.rlp.de/aktuelles/news/detailansicht/nachbericht-pioniergeist-preisverleihung-2022.html [...]
